Ferak Berlin Receives GMP Certification

Thomas Gruendemann, CEO and managing director, Ferak
Thomas Gruendemann, CEO and managing director, Ferak

Berlin, Germany-based provider of contract research & development and custom manufacturing services, Ferak, has received GMP certification by the Berlin State Office for Health and Social Affairs (LAGeSo) for one of its Active Pharmaceutical Ingredients (API). The GMP certificate that has been obtained by help of the Administrative Court of Berlin is immediately available upon request. Prior to the allocation of the certificate an independent GMP expert authorized by the German Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel - BfArM) confirmed full EU-GMP Part II compliance of the manufacturing process and equipment. Further API certificates will follow, the company reports.

“I am more than proud to say that the whole team of Ferak has been working hard to achieve this highest quality standard in the chemical/pharmaceutical industry”, says CEO and managing director Thomas Gruendemann. “The combination of our scientific expertise with both a detailed documentation system and the latest production and analytical equipment is the key to the high purity of our APIs. A clear GMP aim and a zero defect supply chain history with all of our pharmaceutical customers have lead us to this level of excellence which meets exactly our mission statement The Art of Making Purity”, Gruendemann concludes.

Company

Ferak Berlin GmbH

Lahnstr. 34
12055 Berlin
Germany

Company contact







Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

Interview

Stability in Motion
Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.

most read

Photo
14.05.2025 • TopicsPharma

Pharma Outlook 2025

The environment for pharma in 2025 is diverse and challenging: New treatment options are being brought to market in ever shorter cycles.